Get started

Biotech

Is $XBI leading a turn up for QQQ, NDX?Both $QQQ and $XBI made a bullish reversal open on 27 Sep., however QQQ sold down while XBI moved higher. When the daily candle on XBI (or candle pattern) does not match that on QQQ, take note. I have added lines to highlight examples, and these mismatches often occur at turning points with XBI indicating direction for QQQ. It is not a sure predictor, as you can find counter examples also. See end of Jul. and 15 Sep. In the past few months I have found it useful to look at XBI and Bitcoin daily charts when evaluating direction for SPX and NDX.
AMEX:XBI
by OptionsRising
LABU 3X LEVERAGED BIOTECH ETF on support for LONGAMEX:LABU LABU a 3x leveraged EFT in the biotechnology sector has diverse holdings. My thesis is that biotechnology and healthcare are relatively unhinged from the broader general market. On this 15 minute chart, consolidation at support is seen in July, Price then rapidly rose into a triple top in mid-August followed by a descent into a double bottom at the support level. This is a leveraged ETF with good volatility which can be traded. The volume profile of July through mid-August sets a POC as 8,65. This is the best support level within the zone. In the same fashion the volume profile of mid-August through the present sets a POC at 12.45 which is the bottom of the resistance zone. The spread is approximately 40% upside over perhaps two weeks of the expectant uptrend. The zero-lag SMA / EMA oscillator is showing green at its most recent print with an uptrend noted. I will take a trade in a call option with a strike 20 % higher than current price given the potential immediate upside of 40%. I will select an expiration in 4-6 weeks and hope for a 100-200% return.
AMEX:LABULong
by AwesomeAvani
5
Where I'm Buying CPRXCatalyst Pharma (CPRX) is an absolute monster. Not only is the company posting huge sales and earnings growth in a sector that rarely has either, the stock has more than doubled over the last few months. There are 801 stocks in the biotech group tracked by Investors Business Daily, and CPRX ranks at the very top (see image in chart). After such a large advance higher, we must remain cautious to the possibility of a retracement. So we need to see signs of additional strength to trigger an entry. I’m watching for a move above last week’s high for my buy signal. This way, I can place a stop below last week’s low and still get away with a risk of 8% or less on the trade.
NASDAQ:CPRXLong
by rossgivens
NBIX Breakout TradeNBIX is in the biotech sector which I have been highlighting for several months as one of the strongest areas in the market. After emerging from a textbook breakout pattern in early August, shares have consolidated in a tight handle formation. If you look at the relative strength line at the top of the chart, you will notice three pink dots over the last several days. These show the RS line making new highs. Although the stock drifted sideways, the rest of the market has been in an ugly correction, so NBIX is actually holding up better than most other names. I'm looking for a breakout on volume above its down sloping trendline.
NASDAQ:NBIXLong
by rossgivens
$MIRM bear proof 👁‍🗨 *This is not financial advice, so trade at your own risks* *My team digs deep and finds stocks that are expected to perform well based off multiple confluences* *Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management My team entered Mirum Pharmaceuticals $MIRM today at $25 per share. Our take profit is $30. We also have a stop less set at $24 OUR ENTRY: $25 FIRST TAKE PROFIT: $30 STOP LOSS: $24 If you want to see more, please like and follow us @SimplyShowMeTheMoney
NASDAQ:MIRMLong
by SimplyShowMeTheMoney
4
$NRX.V Outpaces Biotech Peers Following TSX.V Listing The biotech sector is presenting exciting opportunities for investors despite the broader downturn in global equity markets. Many of the best biotech companies and ETFs have both strong drug candidate pipelines in the works as well as winning drugs and therapeutic products already on the market. The COVID-19 pandemic has proven and created massive opportunities for the biotechnology sector as a whole, particularly so around innovative players that are developing therapeutic solutions with disruptive potential. One new player to the field is Nurexone Biologic (NRX.V), a new listee on the TSXV exchange that is redefining exosome therapeutics for application to traumatic brain and spinal cord injuries. It is creating a platform for biologically-guided ExoTherapy that will be administered minimally invasively to patients who have had catastrophic spinal cord injuries. Since July 15th, NRX +26% as it attracts new investors and institutional players begin to trade the equity. In comparison, the TSX/SPX composite index charted 6% gains, indicating that NRX far outperformed the market baseline over the course of the summer rally. Relative to sectoral ETFs, Nurexone is also trading strong. IBBQ is +6.9% and XBI +6% over the same timeframe NRX is +26%; it is important to note that over this period, the company did not release any price sensitive announcements that would otherwise account for its significant bullish price movement. Further, exosome-based equities are one area of the wider biotech industry that has continuously traded robustly despite subpar performance for equity markets this year. Sectoral competitors are mixed bag, with KMPH +4.8% while APTO is down 4.4%. Kodiak Biosciences (KOD) jumped 20%, though it still lags behind NRX's 26% increase. This indicates that as exosome therapeutic developers struggle to maintain forward momentum amidst the backdrop of a challenging macroeconomic landscape, NRX is outperforming both sectoral ETFs and direct competitors. Though its a newby to capital markets, so far Nurexone is standing out as the bullish outlier with LT potential.
TSXV:NRX
by BiotechBrandon
BCDA Short AnalysisBCDA has an upcoming CardiAMP Heart Failure DSMB review on the 30th of this month (August). Although the treatment indicated no significant safety concerns, I have reasonable doubt that this won't go through to be accepted by the FDA; the Phase III to NDA/BLA is about a 58.1% chance, the NDA/BLA to Approval is a 85.3% chance, and then the Phase I to Approval is a 9.6% chance. BioCardia has 6 treatments that are under trials and the CardiAMP Ischemic Heart Failure treatment is the closest to approval. If this treatment doesn't get approved, everything will rip apart and the market for this will plunge. Chart-wise, there is a consistent downtrend on the 1-Day mark. If you are putting a short position on this, I highly recommend you to have buy-stop orders.
NASDAQ:BCDAShort
by spamgod
1
MNMD Biotech Penny Stock SHORT SETUPNASDAQ:MNMD Yj This stock had a quick response to good earnings and it is now at resistance with the RSI swing indicator printing a Sell Signal. The MACD, a lagging indicator, shows the signal above the histogram without a K / D cross not yet started. I would like to take a short trade setting a stop loss above the resistance zone and targeting 10% to the POC line of the volume profile sitting above the support zone. Please comment and offer your opinion. 3
NASDAQ:MNMDShort
by AwesomeAvani
8
LABU 3X Leverage BIOTECHNOLOGY a potential Recession playLABU a 3x leveraged EFT in the biotechnology sector has diverse holdings. My thesis is that biotechnology and healthcare are relatively unhinged from the broader general market. Here I chart LABU / QQQ ratio to determine relative strength. On this weekly chart, the ratio and so relative strength are at more than a 52 week low. The MACD indicator shows the MACD and signal line ascending and below the histogram.; moreover the MACD in green is running above the signal line. This favors a trend reversal. All in all, this seems to be a setup for a long swing trade or investment. I will take a trade in a call option with a strike 50% higher than current price as I see a potential for a large percentage gain for LABU. The diversity of the ETF will serve to mitigate some of the risk. A stop loss will be 1% below current price with an expectation of more than a 50 % return in the remainder of the calendar year but far more in the case of the call option scenario
AMEX:LABULong
by AwesomeAvani
LXRX PENNY BIOTECH SHORT SETUPNASDAQ:LXRX LXRX has gained over 100% in the past month However it appears to be forming a double top in a potential short trade setup on the two hour chart. The K/D crossover on the hot RSI oscillator provides confirmation. Short Sale Volume is rising in the past two days. Findamentals - LXRX has a new medication for heart failure a common medical problem with a massive market It recently launched a public offering to raise capital to fund general operations and in doing so diluted the share holders. The good news is it is unlikely to do another in the near term. An entry would be at the current price with a stop loss above the highest volume bar on the profile. The first target is the POC of the volume profile about a 15% price drop . The second target is the pivot low on August 1st for another 15% drop. Taking of 1/2 at each target yields an expected 23% return over a period of about 5 trading days since drops are faster than rises. The call options of mid September have low volumes so I will not consider them.
NASDAQ:LXRXShort
by AwesomeAvani
UBX ( NASDAQ BIOTECH PENNY) crushes earnings and news catalystNASDAQ:UBX and rises over 100 % in premarket, Has a new product for macular degeneration, a widespread medical problem affecting vision in the elderly which is increasing in incidence. The earning beat was significant. Chart demonstrates the uptrend and midrange RSI but does not show today's premarket. 40 % rise in the week leading up to earnings and now parabolic. doubling overnight. * Get in the party now, don't be late. If you are late stay home" ( not a recommendation to buy only education)
NASDAQ:UBXLong
by AwesomeAvani
2